{"entity":{"id":"nct07761429","kind":"trial","name":"A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)","aka":[],"tldr":"A phase 2/3 trial of F520 combined with chemotherapy in cancer of unknown primary, run by Shandong New Time Pharmaceutical Co., LTD, now recruiting.","summary":"A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) is a phase 2/3 interventional study registered as NCT07761429 by Shandong New Time Pharmaceutical Co., LTD, with 402 participants planned, started 2026-07-08 and due to reach its primary completion in 2027-12-30. Interventions recorded: F520 combined with chemotherapy and placebo combined with chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07761429","url":"https://clinicaltrials.gov/study/NCT07761429"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cancer-of-unknown-primary"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07761429","phase":"2/3","setting":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study Evaluating the Safety and Efficacy of F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary","sponsor":"Shandong New Time Pharmaceutical Co., LTD","enrolled":402,"outcomes":[]},"route":"/trials/nct07761429/","neighbours":{"cancer":[{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/"}],"company":[{"id":"shandong-new-time-pharmaceutical","kind":"company","name":"Shandong New Time Pharmaceutical","route":"/companies/shandong-new-time-pharmaceutical/"}]}}